CONMED Co. (NYSE:CNMD – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $79.80.
A number of research analysts recently commented on the company. Needham & Company LLC restated a “buy” rating and issued a $97.00 target price on shares of CONMED in a research note on Friday, October 4th. Stifel Nicolaus dropped their price objective on shares of CONMED from $88.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, August 1st. StockNews.com upgraded shares of CONMED from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Wells Fargo & Company dropped their price target on shares of CONMED from $77.00 to $71.00 and set an “equal weight” rating for the company in a research report on Thursday, August 1st. Finally, Piper Sandler decreased their price objective on CONMED from $95.00 to $80.00 and set an “overweight” rating on the stock in a report on Thursday, August 1st.
View Our Latest Stock Analysis on CNMD
Institutional Trading of CONMED
CONMED Price Performance
Shares of CONMED stock opened at $66.38 on Monday. The firm has a fifty day moving average price of $70.17 and a two-hundred day moving average price of $70.93. CONMED has a fifty-two week low of $61.05 and a fifty-two week high of $117.27. The company has a debt-to-equity ratio of 1.09, a current ratio of 2.34 and a quick ratio of 1.13. The company has a market cap of $2.04 billion, a PE ratio of 25.43, a price-to-earnings-growth ratio of 0.82 and a beta of 1.46.
CONMED (NYSE:CNMD – Get Free Report) last released its earnings results on Wednesday, July 31st. The company reported $0.98 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.06. The business had revenue of $332.10 million for the quarter, compared to the consensus estimate of $334.39 million. CONMED had a return on equity of 13.89% and a net margin of 7.73%. The firm’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period last year, the business earned $0.83 earnings per share. Analysts expect that CONMED will post 3.99 EPS for the current year.
CONMED Announces Dividend
The company also recently declared a quarterly dividend, which was paid on Friday, October 4th. Shareholders of record on Monday, September 16th were given a $0.20 dividend. The ex-dividend date of this dividend was Monday, September 16th. This represents a $0.80 dividend on an annualized basis and a yield of 1.21%. CONMED’s dividend payout ratio (DPR) is presently 30.65%.
CONMED Company Profile
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.
Featured Stories
- Five stocks we like better than CONMED
- Insider Trading – What You Need to Know
- Is Spotify Stock Poised to Soar? Options Traders Think So
- Stock Ratings and Recommendations: Understanding Analyst Ratings
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- How to Invest in Biotech Stocks
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.